FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, immunology and biomedicine, in particular to an improved synthetic T-cell receptor and an antigen receptor (STAR) targeting CD19 and CD20, a T cell comprising a synthetic T cell receptor and an antigen receptor and use thereof.
EFFECT: invention provides obtaining improved TCR and corresponding TCR-T therapy.
43 cl, 45 dwg, 28 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| BINDING DOMAIN | 2019 |
|
RU2829934C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
